The aim of this study is to describe the authors’ experience with intra-arterial ACNU chemotherapy of malignant gliomas. The prognosis of cerebral malignant gliomas remains poor, whatever traditional therapy is applied. ACNU is a well tolerated nitrosourea with a strong antimitotic effect on neurogenic cells both in vitro and in vivo; this drug has enhanced efficacy when used at high concentrations, particularly as an intraarterial infusion. Seventy-six patients have been studied to date, 68 of whom are evaluable; these patients were treated by intraarterial infusion of ACNU (100 mg/m2) every 6 weeks, with a mean of 2.5 courses per patient. The objective response (OR) was 28% and analysis of pretreatment factors revealed that survival was influenced by histological grade, other types of therapy applied, and age. In general IAC is well tolerated and the response and survival appear to be better than with systemic chemotherapy.
AhaleyM.S., WhaleyR.A., BlueM., BertschL.: Central neurotoxicity following intracarotid BCNU chemotherapy for malignant gliomas.J. Neuro-Oncol., 3: 297–314, 1986.
2.
AvellanosaA.M., WestC.R., BaruaN.R.: Treatment of malignant C.N.S.gliomas by intra-arterial BCNU infusion. Proc. Am. Assoc. Cancer Res.,20: 384, 1979.
3.
BambergM., BudachV., StuschkeM., GerhardL.: Preliminary experimental results with the nitrosourea derivative ACNU in treatment of malignant gliomas.Radiother. Oncol., 12: 25–29, 1988.
4.
BoboH., KappJ.P., VanceR.: Effect of intraarterial cisplatin and BCNU dosage on radiographic response and regional toxicity in malignant glioma patients: proposal of a new method of intraarterial dosage calculation.J. Neuro-Oncol., 13: 291–299, 1992.
CalvoF.A., DyC., HenriquezI., HidalgoV., BilbaoI., SantosM.: Post-operative radical radiotherapy with concurrent weekly intraarterial cisplatinum for the treatment of malignant glioma: a pilot study.Radiother. Oncol., 14: 83–88, 1989.
9.
CalvoF.A., PastorM.A., DyC., AlegriaE., AparicioL.M.A., GilA., HarguindeyS., ZubietaJ.L., LageM.M.: Intraarterial and intravenous chemotherapy for treatment of malignant glioma.Am. J. Clin. Oncol., 8: 200–209, 1985.
10.
ChauveineL., SolamartinezM.T., Martin-DuverneuilM., MazeronJ.J., FaillotT., CornuM., CapelleL., DelattreJ.Y., PoissonM., BailletF., ChirasJ.: Intra arterial chemotherapy with ACNU and radiotherapy in inoperable malignant gliomas.J. Neuro-Oncol., 27: 141–147, 1996.
DeVitaV.T., HellmannS., RosenbergS.A. (eds.): Cancer: Principles and practice of oncology, pp. 1438–1439, J.B. Lippincott Company, Philadelphia, 1985.
13.
DewysW.D., FowlerE.H.: Report of vasculitis and blindness after intracarotid injection of 1,3-bis (2-chloroethyl)-nitrosourea (BCNU: NSC-409962) in dogs.Cancer Chemother. Rep., 57: 33–40, 1973.
14.
DropchoE.J., RosenfeldS.S., MorawetzR.B., VitekJ., BrothersM., GorumT., BellS., GillespieG.Y., GlantzM., MahaleyM.S.: Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas: the CNS Cancer Consortium.J. Clin. Onc., 10: 452–458, 1992.
15.
EORTC Brain Tumor Group: Evaluation of CCNU, VM26 plus CCNU and procarbazine in supratentorial brain gliomas.J. Neurosurg., 55: 27–31, 1981.
16.
FenstermacherJ.K., CowlesA.L.: Theoretic limitations of intra-carotid infusion in tumor chemotherapy.Cancer Treat. Rep., 61: 519–526, 1977.
17.
FeunL.G., WallaceS., StewartD.J., ChuangV.P., YungW.A., LeavensM.E., BurgessM.A., SavarajN., BenjaminR.S., YoungS.E., TangR.A., HandelS., MavligitG., FieldsW.S.: Intracarotid infusion of cisplatinum in the treatment of recurrent malignant brain tumors.Cancer, 54: 794–799, 1984.
18.
FujiwaraT., Matsumoto, TsuchidaT., HonnaY., MinoS., NagaoS.: Intraarterial chemotherapy with ACNU in the treatment of malignant gliomas.Gan to Kagaku Ryoho, 19: 489–495, 1992.
19.
GinosJ.Z., CooperA.J., DhawanV., LaiJ.C., StrotherS.C., AlcockN., RottenbergD.A.: Cisplatin PET to assess pharmacokinetics of intraarterial versus intravenous chemotherapy for malignant brain tumors.J. Nucl. Med.,28: 1844–1852, 1987.
20.
GreenS.B., ByarD.P., WalkerM.D.: Comparison of carmus-tine, procarbazine and high-dose methylprednisolone as addition to surgery and radiotherapy for the treatment of malignant glioma.Cancer Treat. Rep.,67: 121, 1983.
21.
GreenbergH.S., EnsmingerW.D., ChandlerW.F., LaytonP.B., JunckL., KnakeJ., VineA.K.: Intraarterial BCNU chemotherapy for treatment of malignant gliomas of central nervous system.J. Neurosurg., 61: 423–429, 1984.
22.
HarperG.P., BlasbergR.G., FenstermacherJ.D., PatlakC.S.: Illustration of intraarterial chemotherapy delivery advantage following intracarotid administration of radiolabelled 2 de-oxy-d-uridine.Proc. Am. Assoc. Cancer Res.,24: 273, 1983 (abstract).
23.
HiesigerE.M., BaslerG.A., LipshutzJ., ShapiroW.R.: Quantitative autoradiographic determination of 14 C-PCNU concentration in C6 rat glioma after intracarotid administration.Proc. Am. Assoc. Cancer Res.,26: 349, 1985.
24.
HoriT., MuraokaK., SaitoV., SasaharaK., InagakiH., InoveY., AdachiS., AnnoY.: Influence of modes of ACNU administration on tissue and blood.J. Neurosurgery, 66: 372–378, 1987.
25.
IwadateY., NambaH., Sue YoshiK.: Intraarterial ACNU and cisplatin chemotherapy for treatment of glioblastoma multiforme.Neurol. Med. Chir. (Tokyo), 35: 598–603, 1995.
26.
KappJ.P., VanceJ.L., ParkerJ.L., SmithR.R.: Limitations of high-dose intraarterial BCNU chemotherapy for malignant gliomas.J. Neurosurg., 10: 715–719, 1982.
KristiansenK., HagenS., KollevoldT.: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of value of postoperative irradiation and lack of potentiation of bleomycin on survival time.Cancer, 47: 619–652, 1981.
29.
KupersmithM.J., SeipleW.H., HolopigianK., NobleK., HiesigerE., WarrenF.: Maculopathy caused by intraarterially administered cisplatin and intravenously administered car-mustine.Am. J. Ophthalmol., 113: 435–438, 1992.
30.
LehaneD.E., BryanR.N., HorowitzB., DesantosL., EhniG., ZubierM.A., MoielR., RudolphL., Aldama-LeubbertA., MahoneyD., HarperR.: Intraarterial cisplatinum chemotherapy for patients with primary and metastatic brain tumors.Cancer Drug Deliv., 1: 69–77, 1983.
31.
LitamJ.P., DailK.H., SpitzerG.: Early pulmonary toxicity after administration of high-dose BCNU.Cancer Treat. Rep., 65: 39–44, 1981.
32.
MadajewiczS., WestC.R., AvellanosaA.M., ParkH.C., GrooraH., TakitaH., KarakousisC., VincentR., CaracandasJ., JenningsE.: Phase II study of intraarterial bis BCNU therapy for metastatic brain tumors.Cancer, 47: 653–657, 1981.
MillerD.F., BayJ.W., LedermanR.J., PurvisJ.D., RogersL.R., TomsakR.L.: Ocular and orbital toxicity following intracarotid injection of BCNU and cisplatinum for malignant gliomas.Ophthalmology, 92: 402–406, 1985.
35.
MitaR., IshiiM., SuzukiM.: Chemotherapy for malignant brain tumor with ACNU, a nitrosourea group agent. Changes in its levels in the blood, cerebrospinal fluid and tumor.Japan J. Cancer Chemother., 5: 1191–1194, 1978.
36.
MortimerJ.E., CrowleyJ., EyreH., WeidenP., EltrighamJ., StuckeyW.J.: A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors. A Southwest Oncology Group Study.Cancer, 69: 1220–1223, 1992.
37.
NewtonH.B., PageM.A., JunckL., GreenbergH.S.: Intra-ar-terial cisplatin for the treatment of malignant gliomas.J. Neuro-Oncol., 7: 39–45, 1989.
38.
PapaveroL., LoewF., JakscheH.: Intracarotid infusion of ACNU and BCNU as adjuvant therapy of malignant gliomas.Acta Neurochir. (Wien), 85: 128–137, 1987.
39.
RebolloJ., Martin-AlgarraS., BilbaoI.: Treatment of supratentorial glioma with intracarotid cisplatin and intravenous carmustine.Neurologia, 5: 228–232, 1990.
40.
RoosenN., Kuwitjc, LinsE., SchirmerM., BockW.J.: Adjuvant intraarterial chemotherapy with nimustine (ACNU) in the management of world health organization grade IV gliomas of brain. Experience in the Department of Neurosurgery of Dusseldorf University.Cancer,64: 1984–1994, 1989.
41.
SoleroC.L., MonfardiniS., BrambillaC.: Controlled study with BCNU vs CCNU as adjuvant chemotherapy following surgery plus radiotherapy for glioblastoma multiforme.Cancer Clin. Trials, 2: 43–48, 1979.
42.
StewartD.J., GrahovacZ., BenoitB., AddisonD., RichardM.T., DenneryJ., HuggenholtzH., RusselN., PetersonE., MarounJ.A., VandenbergT., HopkinsH.S.: Intracarotid chemotherapy with a combination of BCNU, cisplatin, and VM26 in the treatment of primary and metastatic brain tumors.Neurosurgery, 15: 828–833, 1984.
43.
StewartD.J., WallaceS., FeunL., LeavensM., YoungS.E., HaendelS., MavgitG., BenjaminR.S.: A phase I study of intracarotid artery infusion of cisplatinum in patients with recurrent malignant intracerebral tumors.Cancer Res., 42: 2059–2062, 1982.
44.
VanceR.B., KappJ.P.: Supraophthalmic carotid infusion with low dose cisplatin and BCNU for malignant glioma.J. Neuro-Oncol., 3: 287–290, 1986.
45.
WeirB.: The relative significance of factors affecting postoperative survival in astrocytomas grade 3 and 4.J. Neurosurg., 8: 448–452, 1973.
46.
WilsonC.B.: Brain tumors.N. Engl. J. Med., 300: 1469–1471, 1977.
47.
YamadaK., BremerA.M., WestC.R., GhoorahJ., ParkH.C., TakitaH.: Intraarterial BCNU therapy in treatment of metastatic brain tumor from lung carcinoma.Cancer, 14: 2000–2007, 1979.
